// App-Quantinova.ai

POS0192 (2022) : IMPACT OF CORTICOSTEROID DISCONTINUATION ON SYMPTOM CONTROL IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Researchers

Presenter

  • A. Phillips-Beyer

Principal Investigators

  • Q. Li

  • M. E. Stokes

  • M. Pozzobon Da Silva

  • H. Collacott

Medical Centers

  • Innovus Consulting Limited, London, United Kingdom

  • Evidera Inc., Waltham, United States of America

  • Therapeutic Area Units, Idorsia Pharmaceuticals, Allschwil, Switzerland

  • Evidera Ltd, Research, London, United Kingdom

Locations

  • United Kingdom

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Prednisone

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved